Kornimate/medical-research-clean huggingface dataset:
precise oncology interventions in nutrition and training (onpoint)

Conditions: Breast Cancer; Prostate Cancer; Colorectal Cancer

Summary: the purpose of this study is to see if survivors of breast, prostate, or colorectal cancer who receive a personal referral to a targeted nutrition and exercise program will be able to eat a healthier diet and be more physically activity.


Eligibility criteria:
inclusion criteria: inclusion criteria - healthcare providers 1. provide full- or part-time care in an oncology clinical care setting at sylvester comprehensive cancer center 2. utilize the electronic medical record for patient documentation on a regular basis 3. willing to complete a 60-90-minute interview inclusion criteria - patients 1. 18 years of age or older 2. any sex/gender 3. able to provide consent 4. able to read/understand english or spanish 5. diagnosis of breast, prostate or colorectal cancer, 6 months post competition of primary treatment, with no evidence of primary disease 6. approval from treating oncologist, confirmed via email or in writing 7. internet access on a smart phone, tablet, or computer 8. agree to be randomly assigned to any study group exclusion criteria: 1. less than 18 years of age 2. unable to provide consent 3. unable to read/understand english or spanish 4. any contraindication for diet change or exercising as determined by physician 5. blank 6. engaging in \>150 minutes of moderate to vigorous physical activity on average per week for the prior month 7. meeting the american cancer society diet recommendations (3 cups of vegetables or legumes, 2 cups of fruit, 2 serving whole grain per day, and limited red/processed meats, sugar-sweetened beverages, and highly processed foods) for the prior month 8. history of dementia or major psychiatric disease which would interfere with study participation 9. history of recent (≤1 yr) stroke, myocardial infarction or congestive heart failure 10. eastern cooperative oncology group (ecog) score of \>2 11. severe lymphedema as determined by physician 12. receiving physical therapy treatment
evaluation of customized treatment according to brca1 assessment in patients with advanced gastric cancer

Conditions: Advanced Gastric Cancer

Summary: evaluation of customized treatment according to brca1 assessment in patients with advanced gastric cancer


Eligibility criteria:
inclusion criteria: * provision of informed consent * female or male aged 18 years and over * histologic or cytologic confirmation of advanced gastric cancer * stage iii-iv (ajcc 7th) * ecog: 0-2 * have tumor sample that can be tested for brca1 mrna expression * negative pregnancy test for women of childbearing potential * neutrophile granulocyte greater than 1.5×10\^9/l * hemoglobin greater than 10g/dl * platelet greater than 100×10\^9/l * serum bilirubin not greater than 1.5x upper limit of reference range (ulrr) * alt or ast not greater than 1.5x ulrr * creatinine clearance no less than 60ml/min exclusion criteria: * have at least another primary malignant tumor * active infection * chemotherapy with experimental drug within 3 weeks before the start of study therapy * women who are pregnant or breast feeding * weight loss greater 10% within 6 weeks before the start of study therapy

Keywords: gastric cancer, brca1
identification of genetic markers modulating rhythmic risk among patients with severe cardiomyopathy

Conditions: Cardiomyopathy

Summary: the aim of this project is to identify common genetic polymorphisms associated with the occurrence of rhythmic events in patients with severe cardiomyopathy.


Eligibility criteria:
inclusion criteria: * patients implanted for primary prevention, an implantable cardioverter defibrillator (icd) single or double room, for severe cardiomyopathy (ef \<35%) * patients with ischemic cardiomyopathy or idiopathic dilated cardiomyopathy.- "appropriate treatment" group: patients who had a rhythmic event (before or after inclusion) appropriately treated either by administering an electric shock or by antiarrhythmic stimulation * group "no event" patients who have never received treatment or electrical antiarrhythmic stimulation and with a minimum follow-up of three years before inclusion and did not receive proper treatment during the follow up period of the study exclusion criteria: * patients implanted with an icd for primary prevention in the context of a family hereditary disease (long qt syndrome, brugada syndrome, hypertrophic cardiomyopathy, ventricular tachycardia catecholergic right ventricular dysplasia ...). * patients with left ventricular function greater than 35%. * patients implanted with a defibrillator function resynchronization. * patients minors, adults under guardianship and protected persons are eligible under this project.
introducer curving technique for tilt of transfemoral günther tulip inferior vena cava filter

Conditions: Deep Venous Thrombosis

Summary: it has been demonstrated that implantation of inferior vena cava filter was safe and effective in the prevention or reduction of fatal pulmonary thromboembolism in numerous clinical researches. when acute deep venous thrombosis need transcatheter thrombolysis, transfemoral günther tulip filter implantation could avoid catheter across the günther tulip filter. although incidence of significant filter tilting (\>10°) is not high (13%-16%), severe tilting of the günther tulip filter may be associated with difficulty or sometimes impossibility of retrieval. it has been reported that a simple technique of keeping tension of the delivery system may prevent significant tilting of the transjugular günther tulip filter in an in-vitro study. but no clinical study of prevention transfemoral günther tulip filter from tilting has been reported. the investigators conducted a randomized, controlled study to test whether the introducer curving technique is useful to decrease the extent of tilting of transfemoral günther tulip filter.

the study was designed as a double-blind randomized controlled trial, with research assessors and patients intended to be blind to the intervention status. the staff members performing the assessment were not involved in implementing any aspect of the intervention. 108 patients were randomized to accept curving introducer günther tulip filter and transcatheter thrombolysis or straight introducer günther tulip filter and transcatheter thrombolysis. the assessments include the tilting angle between the axes of inferior vena cava and günther tulip filter after implantation; the tilting angle between the axes of inferior vena cava and günther tulip filter before retrieval; the fluoroscopy time of günther tulip filter retrieval; the rate of retrieval hook adhering vascular wall; the success rate of retrieval.

Eligibility criteria:
inclusion criteria: * acute lower extremity deep vein thrombosis, diagnosed by vascular ultrasound and clinical history exclusion criteria: * both lower extremities deep vein thrombosis * inferior vena cava thrombosis * refractory hypertension (blood pressure \> 180/110mmhg) * contraindication of thrombolysis * the diameter of inferior vena cava \> 35mm or \< 14mm * inferior vena cava venous anomalies

Keywords: filter tilt preventional efficiency günther tulip filter transfemoral approach
mechano-physiological approach to anorectal function

Conditions: Constipation

Summary: we hypothesize that defecatory disorders can be described in mechanical terms which would allow a mechanistic description of disorders which would in turn allow better directed biofeedback mechanisms to treat disorders of defecation.

disorders of defecation are very common and the process of defecation remains poorly described. this results in a limited approach to treatment of patients, with limited success. this study will simultaneously measure multiple components of the process of defecation - the abdominal wall and perineal muscle activity, the pressure within the rectum and in the anal canal and the change in shape of the anorectal region of the colon, in order to develop a biomechanical model which can describe the normal and abnormal defecatory process. it is anticipated that, by understanding the process in these terms will allow a new approach to categorizing and describing defecation problems which in turn will lead to more specific approaches of treatment which will be tailored to individual patients. these parameters will compared in volunteers with no defecatory disorders and patients with defecatory disorders who are being referred for defecography as part of their clinical evaluation.

Eligibility criteria:
controls inclusion criteria: * women * no defecatory problems * on no medication which affect bowel habits exclusion criteria: * pregnancy patients inclusion criteria: * difficulty in defecation * women exclusion criteria: * pregnancy * medication which can affect bowel movement

Keywords: defecography pelvic floor dyssynergia anismus
a phase iii study of taci-antibody fusion protein injection (rc18) in subjects with neuromyelitis optica spectrum disorders

Conditions: Neuromyelitis Optica Spectrum Disorders

Summary: the purpose of this study is to initially observe the safety and effectivity of rc18 in participants with neuromyelitis optica spectrum disorders.


Eligibility criteria:
inclusion criteria: * meet the 2015 international consensus diagnostic criteria for neuromyelitis optica spectrum disorders and astrocyte water channel aquaporin-4 (aqp4) antibody positivity. * edss 0-7.5 * clinical evidence of at least 2 relapses within the first two years of randomization and/ or 1 relapse within the first one year of randomization * consent to use effective contraception during the study period (women of childbearing age) * voluntarily signed informed consent exclusion criteria: * abnormal laboratory parameters need to be excluded, including but not limited to: * currently suffering from active hepatitis or serious liver disease and medical history * patients were treated with rituximab or other monoclonal antibodies within 6 months prior to randomization . * any concomitant disease other than neuromyelitis optica（nmo）/ neuromyelitis optica spectrum disorders（nmosd）that required treatment with lucocorticoid. * pregnant , lactating women and men or women who have birth plans during the research; * have a history of allergic reaction to contrast agent for parenteral administration and human biological medicines. * receipt of intravenous immune globulin （ ivig） within 28 days prior to randomization. * receipt of any of the following prior to randomization: azathioprine,cyclosporin, methotrexate mitoxantrone,cyclophosphamide,tocilizumab,tacrolimus,mycophenolate,and patients discontinued more than 5 times the half-life of the drug before they could get into the group .if the patients taking leflunomide and teriflunomide,they should need to take colestyramine for elution. * have participated in any clinical trial in the first 28 days of the initial screening or 5 times half-life period of the study compound (taking shorter time ). * the patients have severe psychiatric symptoms and are not compatible with clinical studies * malignant tumor patients ; * patients experienced any of the following events within 12 weeks before screening : myocardial infarction, unstable ischemic heart disease, stroke, or new york heart association class iv heart failure * patients can't accept magnetic resonance imaging inspection during the trial. * infection with herpes zoster or hiv virus at the screening; * the anti-hepatitis c virus （anti-hcv） of patients show positive; * investigator considers candidates not appropriating for the study.
25-gauge vitrectomy with ranibizumab or triamcinolone acetonide on proliferative diabetic retinopathy in china

Conditions: Proliferative Diabetic Retinopathy

Summary: proliferative diabetic retinopathy(pdr) is the leading cause of visual loss in diabetic patients. operation is an efficient method to treat pdr. anti-vascular endothelial growth factor (anti-vegf) can be used as an adjuvant therapy which can make operation more easy.

proliferative diabetic retinopathy(pdr) is the leading cause of visual loss in diabetic patients. the operation indication includes non-absorbed vitreous haemorrhage, dense bleeding in front of the macular, proliferative vitreoretinopathy traction macular, tractional retinal detachment combined break, severe progressive fiber vascular proliferation and vitreous haemorrhage combined with early iris neovascularization. due to vegf levels rise in vitreous cavity of pdr patients, some inflammatory cytokines involved in, make easy bleeding during surgery and heavier inflammatory reaction postoperation,thus affecting the curative effect of the operation. ranibizumab as angiogenesis inhibitors, has widely applied in the treatment of age-related macular degeneration, won the recognition of ophthalmologists. some scholars try to expand the application in diabetic macular edema, also obtained the good curative effect.some scholars also applied the angiogenesis inhibitors to the diabetes retinopathy before surgery in the hope to reduce the occurrence of intraoperative bleeding.compared with bevacizumab, the short half-life of lucentis, and thus reduce the inhibition of vegf system risk. in this project, the investigators will inject lucentis into vitreous cavity before surgery of pdr, and observe the effect and complications of the operation, compared with triamcinolone acetonide group(the control group); at the same time the cytokines level of vegf, pigment epithelium-derived factor (pedf), epidermal growth factor (egf), transforming growth factor-beta (tgf-beta), interleukin 6 (il - 6) and interleukin 8 (il - 8) will be detected before and after pretreatment with lucentis or triamcinolone acetonide, and the cytokines concentration change will be compared between two groups, the mechanism of pdr will be further clarified and theoretical basis for looking for treatment strategies will be laid.

Eligibility criteria:
inclusion criteria: * type ii diabetes mellitus with diabetic retinopathy * vitreous hemorrhage/proliferation of retinal/tractional detachment of retina * fasting blood-glucose no more than 8mmol/ml exclusion criteria: * subjects who have operation on vitreous before * accompany with other ophthalmology diseases except cataract * history of vitrectomy surgery in the study eye * previous subfoveal focal laser photocoagulation in the study eye * previous participation in a clinical trial (for either eye) * previous subfoveal focal laser photocoagulation in the study eye * other diseases cannot afford vitrectomy

Keywords: lucentis ranibizumab triamcinolone acetonide vitrectomy pdr
integrated approaches for identifying molecular targets in alcoholic hepatitis

Conditions: Alcoholic Hepatitis; Control Patients

Summary: purpose: to improve the diagnosis and assessment of severity of acute alcoholic hepatitis participants: patients admitted to one of ten centers with acute alcoholic hepatitis procedures (methods): consecutive patients admitted with acute alcoholic hepatitis will be enrolled in an nih u01 study of acute alcoholic hepatitis where liver tissue, blood and stool will be collected to discover and validate factors associated with diagnosis, severity of disease and survival.

the development of new targeted therapies for alcoholic hepatitis (ah) is one of the more urgent needs in clinical hepatology. to reach this goal, large multidisciplinary networks are required. the proposed initiative "integrated approaches for identifying molecular targets in alcoholic hepatitis" (inteam) will coordinate a multidisciplinary group composed of clinicians, physician-scientists, basic scientists and bioinformatics experts. the overarching hypothesis of inteam is that the most rational way to provide a useful framework for future clinical trials in (ah) consists of the (i) determination of key drivers of the disease process, (ii) classification of molecular profiles and subtypes of ah, and (iii) identification of "druggable" targets based on both key drivers and molecular classification. moreover, mouse models for ah are lacking making it impossible to evaluate promising targets in preclinical mouse studies in a meaningful manner. for this purpose, inteam will integrate data obtained from molecular pathology studies in human ah and functional studies of key pathways in animal models. the proposed inteam consortium includes three research projects, ten clinical centers, a human biorepository and a mouse models core. the human biorepository core will generate the to-date largest collection of samples from patients with ah from 10 academic liver centers and a comprehensive database that will serve as a basis for the proposed translational studies and be a valuable asset for the broader scientific community. the mouse models core will conduct murine studies after establishing and evaluating mouse models of ah based on the pathophysiology and molecular drivers of human ah determined by this consortium.

Eligibility criteria:
inclusion criteria: * patients 18 ≥ and ≤ 70 years of age. * active alcohol abuse within the past 3 months. * has an aspartate aminotransferase (ast) \> alanine aminotransferase (alt). * elevated total bilirubin level \> 3.0. * absence of autoimmune liver disease (ana\>1/320). * absence of hepatitis b infection. * a liver biopsy, and/or a clinical picture consistent with alcoholic hepatitis. * the "start date" (is the date of the liver biopsy or ≤ to 1 week \[72 hours is preferred\] from the time of admission). exclusion criteria: * hepatocellular carcinoma. * complete portal vein thrombosis. * advanced or terminal extrahepatic diseases. * lack of consent to participate in the study. * pregnancy. * received more than 3 days of treatment with (prednisolone or pentoxifyllin) prior to start date. control patients
study of obatoclax in previously untreated acute myeloid leukemia (aml)

Conditions: AML

Summary: this protocol will evaluate the efficacy of obatoclax in older patients with previously untreated aml.

the pilot safety portion of the study will evaluate the safety of obatoclax administered by a 3 hour infusion for 3 days in a row. the pilot schedule portion of the study will randomize 16 patients in to one of two cohorts: 1) patients receiving obatoclax administered by a 3 hour infusion for 3 days in a row or 2) patients receiving obatoclax administered by a 24 hour infusion for 3 days in a row. the schedule with the best overall efficacy and safety in the pilot schedule portion of the study will then be utilized in the phase ii portion of the study.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed aml * no prior chemotherapy for aml (with the exception that the patients enrolled in the pilot safety evaluation may have had 1 prior therapy) * age ≥70 years * eastern cooperative oncology group (ecog) performance status ≤2 * patients must have normal organ function as defined below: 1. total bilirubin \< or = 2 mg/dl unless resulting from hemolysis, 2. aspartate transaminase (ast \[sgot\])/alanine transaminase (alt \[sgpt\]) \< or = 2.5 x institutional uln 3. creatinine within normal institutional limits, or creatinine clearance \> or = 50 ml/min/1.73 meters squared for patients with creatinine levels above institutional uln exclusion criteria: * patients who have received or are receiving any other investigational or commercial agents or therapies administered with the intent to treat their malignancy (with the exception that the patients enrolled in the pilot safety evaluation may have had 1 prior therapy) * patients with history of allergic reactions attributed to components of the formulated product (peg300 and polysorbate 20) * patients with history of seizure disorders or central nervous system leukemia * patients with uncontrolled, intercurrent illness including, but not limited to, symptomatic neurological illness; active, uncontrolled, systemic infection considered opportunistic, life-threatening, or clinically significant at the time of treatment; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; significant pulmonary disease or hypoxia; or psychiatric illness/social situations that would limit compliance with study requirements * human immunodeficiency virus (hiv)-positive patients receiving combination anti-retroviral therapy

Keywords: aml, obatoclax
anti-xa level with thromboprophylactic dosage nadroparin in critically ill covid-19 and non-covid-19 patients

Conditions: Critical Illness; Therapeutic Drug Monitoring; Venous Thromboembolism

Summary: primary objective the objective of this study is to compare anti-xa levels obtained with a standard high dose thrombosis prophylaxis in covid-19 intensive care-patients compared with anti-xa levels obtained with a normal dose thrombosis prophylaxis in non-covid-19 intensive care patients. secondary objectives 1. to determine the incidence of anti xa levels out of range of the established target anti xa level in both groups. 2. to determine the influence of relevant co-variates on the anti-xa level in the covid-19 and non-covid-19 group.


Eligibility criteria:
inclusion criteria: * all covid-19 patients \> 18 years admitted at the icu using nadroparin in a high thrombosis prophylactic dosage of 1 dd 5700 iu or 2 dd 5700 iu sc * all medical non-covid-19 patients admitted at the icu using nadroparin in a standard prophylactic dosage of 1 dd 2850 iu sc. * minimum estimated length of stay on the icu of 4 days exclusion criteria: o (history of) heparin induced thrombocytopenia and thrombosis
long-term follow-up of broad spectrum human papillomavirus (hpv) vaccine study in women (v503-021)

Conditions: Cervical Cancer; Vulvar Cancer; Vaginal Cancer; Genital Warts; Human Papillomavirus Infection

Summary: protocol v503-021 is a long-term follow-up study of the v503-001 base study (nct00543543) to evaluate the safety, immunogenicity, and long-term effectiveness of v503 vaccine in preventing cervical cancer and related precancers caused by human papillomavirus (hpv) types 16, 18, 31, 33, 45, 52, and 58. because of the high retention of v503-001 participants from the nordic countries, and the highly efficient screening and surveillance system there, study v503-021 will evaluate only participants from v503-001 sites in denmark, norway, and sweden. the hypothesis is that v503 vaccine will remain effective for at least 30 years after the start of vaccination.


Eligibility criteria:
inclusion criteria: * randomized into the v503-001 (nct00543543) study from a denmark, norway, or sweden site and participated in the study by receiving either the selected dose formulation of v503 or gardasil * agrees to allow passive follow-up, analysis of biopsy specimens, future contact from the national registry study centers, and serum collection exclusion criteria: - there are no exclusion criteria